Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silo Pharma (SILO) Asset Writedowns and Impairment (2020 - 2022)

Silo Pharma's Asset Writedowns and Impairment history spans 3 years, with the latest figure at -$20000.0 for Q1 2022.

  • For Q1 2022, Asset Writedowns and Impairment fell 166.67% year-over-year to -$20000.0; the TTM value through Dec 2022 reached -$20000.0, up 86.53%, while the annual FY2022 figure was -$20000.0, 86.53% up from the prior year.
  • Asset Writedowns and Impairment for Q1 2022 was -$20000.0 at Silo Pharma, up from -$65000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $196500.0 in Q4 2020 and bottomed at -$65000.0 in Q4 2021.
  • The 3-year median for Asset Writedowns and Impairment is -$28750.0 (2021), against an average of $4666.7.
  • The largest annual shift saw Asset Writedowns and Impairment plummeted 133.08% in 2021 before it crashed 166.67% in 2022.
  • A 3-year view of Asset Writedowns and Impairment shows it stood at $196500.0 in 2020, then crashed by 133.08% to -$65000.0 in 2021, then soared by 69.23% to -$20000.0 in 2022.
  • Per Business Quant, the three most recent readings for SILO's Asset Writedowns and Impairment are -$20000.0 (Q1 2022), -$65000.0 (Q4 2021), and -$37500.0 (Q3 2021).